THE OCULAR SAFETY OF HYDROXYCHLOROQUINE

被引：51

作者：

EASTERBROOK, M

机构：

[1] WELLESLEY COLL HOSP,TORONTO M4Y 1J3,ON,CANADA

[2] PRINCESS MARGARET HOSP,TORONTO M4X 1K9,ON,CANADA

[3] ORTHOPED & ARTHRIT HOSP,TORONTO,ON,CANADA

[4] TORONTO GEN HOSP,TORONTO,ON,CANADA

[5] WESTERN HOSP,TORONTO,ON,CANADA

来源：

SEMINARS IN ARTHRITIS AND RHEUMATISM | 1993年 / 23卷 / 02期

关键词：

HYDROXYCHLOROQUINE; OCULAR SAFETY; MACULOPATH; KERATOPATHY; AMSLER; COLOR VISION;

D O I：

10.1016/S0049-0172(10)80009-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The insert currently supplied with hydroxychloroquine states that patients should have an initial ophthalmological assessment and then regular assessments every 3 months. The rheumatologist should expect a report from the ophthalmologist, which includes a corneal assessment of tissue dose, a reference to visual field defects if present on the Amsler grid, and a comment concerning the status of the patient's color vision. Daily dose is more important than duration of dose, regarding maculopathy. The visual prognosis of retinopathy is excellent if the diagnosis is made at an early stage of the disease. This report suggests that ophthalmological review need only occur initially and on a yearly basis if the daily dose of hydroxychloroquine is less than 6.5 mg/kg/d and the duration of therapy is less than 9 years. © 1993, W.B. Saunders Company. All rights reserved.

引用

页码：62 / 67

页数：6

共 25 条

[11]

EASTERBROOK M, 1985, T OPHTHAL SOC UK, V104, P204

[12] OCULAR EFFECTS AND SAFETY OF ANTIMALARIAL AGENTS [J].